retatrutide glp-1 gip glucagon receptor Retatrutide, a GIP, and agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA Retatrutide online: complete guide to

Description

If you are struggling with loss of vision or changes to your health due to taking GLP-1 drugs, you may have the right to seek legal action against the manufacturer

On May 22nd, federally-registered compounding facilities will stop making compounded GLP-1s in response to the U.S.

The Gallup Poll found that overall, use of semaglutide medicines or liraglutides doubled from nearly 6% in the first quarter of 2024 to over 12% in Q2 + Q3 in 2025

It's a fillip for new Novo Nordisk chief executive Mike Doustdar, who took the helm last year with a clear remit to defend the GLP-1-based weight loss and diabetes business from rivals like Eli Lilly, as well as knock-off versions of semaglutide that sidestep the company's intellectual property (IP).